Allocation of public sources in oncology: Which role can ethics play?

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1129-1131

  Bernardi, Alessandra ^a   Jirillo, A ^a   Pegoraro, R ^b   Bonavina, M G ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Fondazione Lanza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER; CANCER SURVIVAL; CONFLICT OF INTEREST; COST CONTROL; DOCTOR PATIENT RELATION; DRUG COST; ECONOMIC ASPECT; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HUMAN; MEDICAL ETHICS; MORALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; RESOURCE ALLOCATION; SOCIAL ASPECT;

ANTINEOPLASTIC AGENTS; COST ALLOCATION; HEALTH CARE COSTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 34547852277     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm129     Document Type: Editorial

References (17)

1. http://www.imshealth.com/ims/portal/pages/homeFlash/europe/ 0,2768,6025,00.html.
2. Wilking N, Jönsson B. A pan-European comparison regarding patient access to cancer drugs, 2005; http://ki.se/ki/jsp/ polopoly.jsp?d=933&;a=3315&cid=940&l=en. (10 April 2007, date last accessed).
3. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89-103.
4. Schwartz WB, Mendelson DN. Eliminating waste and inefficiency can do little to contain costs. Health Aff (Millwood) 1994; 13: 224-238.
5. Zweifel P, Steinmann L, Eugster P. The Sisyphus syndrome in health revisited. Int J Health Care Finance Econ 2005; 5: 127-145.
6. Kilner JF. Allocation of health-care resources: II. Microallocation. In Reich WT (ed): Encyclopedia of Bioethics. New York, NY: Simon and Schuster Macmillan, 1995; 1075-1084.
7. Ubel PA, Goold Dorr S. Rationing health care: Not all definitions are created equal. Arch Int Med 1998; 158: 209-214.
8. Sulmasy DP. Cancer care, money, and value of life: Whose justice? Which rationality?. J Clin Oncol 2007; 25: 217-222.
9. Irons R. The therapeutic Covenant. Paradigm; Fall 2001: 6-7. http://www.prckansas.org/articles/Covenant.htm.
10. Brothers K. Covenant and the vulnerable other. JAMA 2002; 288: 1133.
11. Hurst SA, Slowther AM, Forde R et al. Prevalence and determinants of physician bedside rationing, J Intern Med 2006; 21: 1138-1143.
12. Hurst SA, Hull SC, DuVal G, Danis M. How physicians face ethical difficulties: A qualitative analysis. J Med Ethics 2005; 31: 7-14.
13. Gilmer T, Schneiderman LJ, Teetzel H et al. The costs of nonbeneficial treatment in the intensive care setting. Health Aff (Millwood) 2005; 24: 961-971.
14. Schneiderman LJ, Gilmer T, Teetzel HD. Impact of ethics consultations in the intensive care setting: A randomized, controlled trial. Crit Care Med 2000; 28: 3920-3924.
15. Levin PD, Sprung CL. Are ethics consultations worthwhile?. Crit Care Med 2000; 28: 3942-3944 [editorial].
16. Pochard F, Azoulay E, Chevret S, Zittoun R. Toward an ethical consultation in intensive care?. Crit Care Med 2001; 29: 1489-1490 [letter to the editor].
17. Thurber CF. Assessing quality in the HCOs: A paradigm for organizational ethics. HEC Forum 1999; 11: 358-363.